| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $1,180,007 ) |
| | 2023 | 2023 | ZALGEN LABS, LLC | 7495 NEW HORIZON WAY STE 120 | FREDERICK | MD | 21703-8388 | FREDERICK | USA | R01AI141251 | Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies | 000 | 5 | NIH | 11/23/2022 | $1,180,007 |
|
| Issue Date FY: 2022 ( Subtotal = $1,192,954 ) |
| | 2022 | 2022 | ZALGEN LABS | 20271 GOLDENROD LN STE 2083 | GERMANTOWN | MD | 20876-4125 | MONTGOMERY | USA | R01AI141251 | Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies | 000 | 4 | NIH | 12/8/2021 | $1,192,954 |
| | 2022 | 2019 | ZALGEN LABS, LLC | 7495 NEW HORIZON WAY STE 120 | FREDERICK | MD | 21703-8388 | FREDERICK | USA | R43AI138836 | Glycoprotein Immunoassay to Measure Protective Response to Lassa Vaccine | 000 | 2 | NIH | 10/14/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,225,955 ) |
| | 2021 | 2021 | ZALGEN LABS | 20271 GOLDENROD LN STE 2083 | GERMANTOWN | MD | 20876-4125 | MONTGOMERY | USA | R01AI141251 | Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies | 001 | 3 | NIH | 11/20/2020 | $1,202,174 |
| | 2021 | 2020 | ZALGEN LABS | 20271 GOLDENROD LN STE 2083 | GERMANTOWN | MD | 20876-4125 | MONTGOMERY | USA | R01AI141251 | Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies | 000 | 2 | NIH | 10/19/2020 | $23,781 |
|
| Issue Date FY: 2020 ( Subtotal = $1,198,401 ) |
| | 2020 | 2020 | ZALGEN LABS | 20271 GOLDENROD LN STE 2083 | GERMANTOWN | MD | 20876-4125 | MONTGOMERY | USA | R01AI141251 | Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies | 000 | 2 | NIH | 12/17/2019 | $1,198,401 |
|
| Issue Date FY: 2019 ( Subtotal = $1,797,448 ) |
| | 2019 | 2019 | ZALGEN LABS | 20271 GOLDENROD LN STE 2083 | GERMANTOWN | MD | 20876-4125 | MONTGOMERY | USA | R43AI138836 | Glycoprotein Immunoassay to Measure Protective Response to Lassa Vaccine | 000 | 2 | NIH | 2/22/2019 | $299,050 |
| | 2019 | 2019 | ZALGEN LABS | 20271 GOLDENROD LN STE 2083 | GERMANTOWN | MD | 20876-4125 | MONTGOMERY | USA | R01AI141251 | Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies | 000 | 1 | NIH | 12/24/2018 | $1,498,398 |
|
| Issue Date FY: 2018 ( Subtotal = $379,749 ) |
| | 2018 | 2018 | ZALGEN LABS | 20271 GOLDENROD LN STE 2083 | GERMANTOWN | MD | 20876-4125 | MONTGOMERY | USA | R43AI138836 | Glycoprotein Immunoassay to Measure Protective Response to Lassa Vaccine | 001 | 1 | NIH | 8/21/2018 | $198,184 |
| | 2018 | 2018 | ZALGEN LABS | 20271 GOLDENROD LN STE 2083 | GERMANTOWN | MD | 20876-4125 | MONTGOMERY | USA | R43AI138836 | Glycoprotein Immunoassay to Measure Protective Response to Lassa Vaccine | 000 | 1 | NIH | 3/16/2018 | $298,900 |
| | 2018 | 2016 | ZALGEN LABS | 20271 GOLDENROD LN STE 2083 | GERMANTOWN | MD | 20876-4125 | MONTGOMERY | USA | R44AI088843 | Recombinant antigen diagnostics for filoviruses | 000 | 5 | NIH | 2/1/2018 | -$6,191 |
| | 2018 | 2016 | ZALGEN LABS | 20271 GOLDENROD LN STE 2083 | GERMANTOWN | MD | 20876-4125 | MONTGOMERY | USA | R44AI115754 | Late-stage development toward commercialization of multilineage point-of-care Lassa fever diagnostics | 000 | 2 | NIH | 12/5/2017 | -$111,144 |
|
| Issue Date FY: 2017 ( Subtotal = -$6,252 ) |
| | 2017 | 2015 | ZALGEN LABS | 20271 GOLDENROD LN STE 2083 | GERMANTOWN | MD | 20876-4125 | MONTGOMERY | USA | R43AI120472 | Evaluation of fully human Pan-Old World Arenavirus monoclonal antibodies as candidate therapeutics for LCMV infection | 000 | 1 | NIH | 12/13/2016 | -$6,252 |
|
| Issue Date FY: 2016 ( Subtotal = $1,928,504 ) |
| | 2016 | 2016 | ZALGEN LABS | 20271 GOLDENROD LANE | GERMANTOWN | MD | 20876 | MONTGOMERY | USA | R44AI088843 | Recombinant antigen diagnostics for filoviruses | 000 | 5 | NIH | 6/28/2016 | $1,000,000 |
| | 2016 | 2016 | ZALGEN LABS | 20271 GOLDENROD LANE | GERMANTOWN | MD | 20876 | MONTGOMERY | USA | R44AI088843 | Recombinant antigen diagnostics for filoviruses | 001 | 5 | NIH | 7/19/2016 | $558,186 |
| | 2016 | 2016 | ZALGEN LABS | 20271 GOLDENROD LANE | GERMANTOWN | MD | 20876 | MONTGOMERY | USA | R44AI088843 | Recombinant antigen diagnostics for filoviruses | 001 | 5 | NIH | 7/19/2016 | -$558,186 |
| | 2016 | 2016 | ZALGEN LABS | 20271 GOLDENROD LANE | GERMANTOWN | MD | 20876 | MONTGOMERY | USA | R44AI115754 | Late-stage development toward commercialization of multilineage point-of-care Lassa fever diagnostics | 000 | 2 | NIH | 1/15/2016 | $928,504 |
|
| Issue Date FY: 2015 ( Subtotal = $1,075,308 ) |
| | 2015 | 2015 | ZALGEN LABS | 20271 GOLDENROD LANE | GERMANTOWN | MD | 20876 | MONTGOMERY | USA | R44AI115754 | Late-stage development toward commercialization of multilineage point-of-care Lassa fever diagnostics | 000 | 1 | NIH | 2/2/2015 | $927,590 |
| | 2015 | 2015 | ZALGEN LABS | 20271 GOLDENROD LANE | GERMANTOWN | MD | 20876 | MONTGOMERY | USA | R43AI120472 | Evaluation of fully human Pan-Old World Arenavirus monoclonal antibodies as candidate therapeutics for LCMV infection | 000 | 1 | NIH | 7/1/2015 | $147,718 |
|
|
